Exelixis, Inc. (Exelixis) is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

Research Grants 8 show all


$198K
1995

$55K
1997

$64.8K
1999

$6M
2000

$95.4K
2001

Patents 2,291show all

  • 452
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 392
    C07D - Heterocyclic compounds
  • 331
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 283
    A61K - Preparations for medical, dental, or toilet purposes
  • 233
    C07K - Peptides
  • 212
    C12N - Microorganisms or enzymes
  • 92
    A01K - Animal husbandry
  • 24
    A61N - Electrotherapy
  • 23
    A01H - New plants or processes for obtaining them
  • 22
    C07C - Acyclic or carbocyclic compounds

Clinical Trials 174show all

59Phase 335Phase 233Phase 132N/A14Other

SEC Filings show all


260
8-K

61
10-Q

20
10-K

2
D

1
S-1

Contact Information

1851 Harbor Bay Parkway
Alameda, CA 94502
United States

Overview

Total FundingEmployeesLast Funding DateStatus
251-500Ipo

SEC Form D Funding Events

DateOfferedSoldType
2009-07-16$3,025,000$0Equity, Option to Acquire, Other
2008-06-27Unknown Unknown Other (Paper Filing)

Key Executives

  • George A. Scangos
    Executive Officer, Director
  • Michael M. Morrissey
    Executive Officer
  • Frances K. Heller
    Executive Officer
  • Frank L. Karbe
    Executive Officer
  • Gisela M. Schwab
    Executive Officer
  • Pamela A. Simonton
    Executive Officer
  • Peter Lamb
    Executive Officer
  • Lupe M. Rivera
    Executive Officer
  • Stelios Papadopoulos
    Director
  • Charles Cohen
    Director
  • Carl B. Feldbaum
    Director
  • Alan M. Garber
    Director
  • Vincent T. Marchesi
    Director
  • Frank McCormick
    Director
  • George Poste
    Director
  • Lance Willsey
    Director
  • Jack L. Wyszomierski
    Director